SCIENCE & TECHNOLOGY

CoDa Therapeutics is building a portfolio of novel, proprietary anti-connexin compounds that modulate gap junctions and reduce cell to cell communication post-injury. Effective in a variety of tissue types including, eye, skin, spinal cord and brain, gap junction modulation has been shown in numerous pre-clinical models to reduce lesion spread (cell death), swelling, inflammation, scarring and time to wound closure.